Department of Obstetrics and Gynecology, First Affiliated Hospital, School of Medicine, Shihezi University, Shihezi, China.
The NHC Key Laboratory of Prevention and Treatment of Central Asia High Incidence Diseases, First Affiliated Hospital, School of Medicine, Shihezi University, Shihezi, China.
Pathol Oncol Res. 2021 Dec 17;27:1610006. doi: 10.3389/pore.2021.1610006. eCollection 2021.
To investigate whether serum Tie-1 (sTie-1) is a valuable marker for predicting progression and prognosis of cervical cancer. Enzyme-linked immunosorbent assay (ELISA) was used to detect serum sTie-1 concentrations in 75 cervical cancer patients, 40 cervical intraepithelial neoplasia (CIN) patients, and 55 healthy controls without cervical lesions, and sTie-1 levels were compared between the groups. Receiver operating characteristic curves was used to evaluate the diagnostic value of sTie-1. The relationship between sTie-1 concentrations in patients with cervical cancer and clinicopathological features and prognosis were analyzed, and the risk factors for postoperative recurrence were determined using univariate and multivariable Cox proportional hazards regression. We found that sTie-1 concentrations gradually increased according to lesion severity (i.e., cancer vs. CIN; < 0.05) and were significantly elevated in adenocarcinoma compared with healthy controls. sTie-1 levels strongly distinguished between cervical cancer patients and the healthy controls (area under the curve = 0.846; cut-off value = 1,882.64 pg/ml; sensitivity = 74.6%; specificity = 96.4%). Moreover, sTie-1 levels in cervical cancer patients were significantly associated with tumor size, advanced tumor stage, lymph node metastasis, and reduced 4-years progression-free survival. Cervical cancer patients with high sTie-1 concentrations had a 3.123-fold [95% confidence interval (CI): 1.087-8.971, = 0.034] higher risk for tumor recurrence. Elevated sTie-1 levels in patients with cervical carcinoma were associated with tumor progression and poor prognosis, indicating that sTie-1 may be a valuable marker for predicting progression and prognosis of cervical cancer.
探讨血清 Tie-1（sTie-1）是否可作为预测宫颈癌进展和预后的有价值标志物。方法：采用酶联免疫吸附试验（ELISA）检测 75 例宫颈癌患者、40 例宫颈上皮内瘤变（CIN）患者和 55 例无宫颈病变的健康对照者血清 sTie-1 浓度，比较各组间 sTie-1 水平。采用受试者工作特征曲线评估 sTie-1 的诊断价值。分析宫颈癌患者 sTie-1 浓度与临床病理特征和预后的关系，并采用单因素和多因素 Cox 比例风险回归确定术后复发的危险因素。结果：sTie-1 浓度随病变严重程度逐渐升高（即癌症 vs. CIN； < 0.05），腺癌患者显著高于健康对照组。sTie-1 水平可将宫颈癌患者与健康对照组很好地区分（曲线下面积=0.846；截断值=1,882.64 pg/ml；灵敏度=74.6%；特异性=96.4%）。此外，宫颈癌患者的 sTie-1 水平与肿瘤大小、晚期肿瘤分期、淋巴结转移和降低的 4 年无进展生存率显著相关。sTie-1 浓度较高的宫颈癌患者肿瘤复发风险增加 3.123 倍（95%可信区间：1.087-8.971， = 0.034）。结论：宫颈癌患者 sTie-1 水平升高与肿瘤进展和不良预后相关，表明 sTie-1 可能是预测宫颈癌进展和预后的有价值标志物。
